mRNA Cancer Therapy Meets Phase 3 Goals, Plus 3 Stories
Friday’s biggest technology story is the kind where optimism and restraint have to sit in the same paragraph. Moderna and Merck say a personalized mRNA treatment for melanoma met the main goals of a large Phase 3 trial. That is genuinely significant. It is also not the same thing as “mRNA cures cancer,” no matter how badly the headline-writing part of the internet may want to skip ahead.
Elsewhere, Microsoft fixed a Copilot Personal flaw that shows why connecting AI assistants to everything creates new kinds of security problems, Apple has once again rewritten the rules for distributing and selling apps in the European Union, and Firefox has a security update worth restarting those 47 tabs for.
Personalized mRNA melanoma therapy met its Phase 3 goals
Moderna and Merck say their investigational personalized cancer treatment, intismeran autogene, produced a clinically meaningful improvement in recurrence-free survival when combined with Keytruda in a 1,137-patient Phase 3 melanoma trial.
The treatment is better described as an individualized neoantigen therapy than a traditional vaccine. Doctors analyze a sample of a patient’s tumor for mutations that create distinctive proteins, then build a custom mRNA treatment intended to teach that person’s immune system what to recognize as a target.
Patients in the INTerpath-001 study had Stage IIB through Stage IV melanoma that had been completely removed. They received either the personalized mRNA treatment plus Keytruda or Keytruda alone. The companies say the combination met the primary goal involving recurrence-free survival and a key secondary goal involving distant metastasis-free survival — essentially, whether the cancer spread elsewhere in the body.
This is the first positive late-stage trial result for this kind of personalized mRNA cancer treatment, according to Reuters. That is a real milestone. The caveat is that we still have top-line results rather than the complete dataset. The companies had not yet publicly released the full numerical results, and overall-survival data were still being followed.
So we know the trial met the goals it was designed to measure. We do not yet know everything we would want to know about the size of the benefit, how durable it will be, or how the treatment will perform outside a clinical trial. There is nothing melanoma patients need to go ask for tomorrow morning. But if the detailed data hold up and regulators agree, personalized cancer medicine just moved a substantial step closer to ordinary medicine rather than an extremely expensive science project.
Technology is rarely just about the technology
Some of the most important technology stories aren’t product launches at all. They’re about health, privacy, education, law, accessibility, work, and what happens when technology reaches ordinary people. Browse more Raymond Tec News for the stories worth understanding without the hype.
A patched Copilot flaw shows why connected AI changes the blast radius
Microsoft fixed an 8.8-severity flaw in Copilot Personal that researchers at Varonis called CoSnitch. There is no evidence it was exploited in the wild, Microsoft says the issue is fixed, and customers do not need to take action.
The interesting part is how the attack worked. A specially crafted link could feed an attacker-controlled prompt into an authenticated Copilot session. From there, Varonis says it chained weaknesses involving Copilot’s connected-service access and memory. If a user had authorized Copilot to reach Gmail, Google Drive, Google Calendar, OneDrive or similar services, the assistant could potentially be manipulated into retrieving information and sending it somewhere the attacker controlled.
This was Copilot Personal, not Microsoft 365 Copilot for work or school accounts. Enterprise customers were unaffected. Still, the design lesson matters beyond this bug.
We are deliberately giving AI assistants permission to cross email, calendars, cloud storage and documents because that is what makes them useful. Every new connection also increases what a successful prompt-injection or authorization flaw can reach. A chat-shaped interface can now hold application-shaped permissions.
The useful habit is the same one we should already use with any application holding broad access to data: connect only what you actually need, periodically review permissions, and do not assume “it looks like a chat box” means “it has the security consequences of a chat box.” Increasingly, it does not.
Turning on AI is the easy part
Deciding what an AI tool should be allowed to see, who should use it, what work it should perform, and what happens when it gets something wrong is the more interesting problem. Raymond Tec helps businesses connect and automate the tools they actually use without treating every new feature like a button that obviously needs to be switched on.
Apple opens the EU App Store doors wider — and keeps charging admission
Apple is rewriting its European Union app-business terms again, with new unified rules taking effect October 1. The old per-install Core Technology Fee is being replaced by a 5% Core Technology Commission on digital transactions for apps distributed outside the App Store, including alternative marketplaces and direct web distribution.
For App Store apps using alternative payment processors, Reuters reports Apple will generally charge a 20% commission, potentially falling to 10% for eligible small-business-program developers. Developers will also be able to offer Apple In-App Purchase alongside another payment method instead of choosing one or the other.
This is part of the long-running fallout from the EU’s Digital Markets Act, which requires designated gatekeepers to allow more competition around software distribution and payments. The European Commission welcomed the changes and says it will watch how they are implemented. Epic Games, unsurprisingly, remains much less impressed.
For ordinary U.S. iPhone owners, nothing changes October 1. For developers selling digital goods to EU customers, distribution channel, payment method and program eligibility can materially change how much of a sale goes to Apple. Regulators forced open doors Apple spent years insisting needed to stay closed. The doors are more open now. Apple is still charging admission.
The rules around technology matter too
Platforms, privacy, speech, competition, surveillance, copyright, and regulation increasingly determine what technology companies can build and what the rest of us have to live with. Browse more Raymond Tec News for practical coverage of technology policy and digital rights.
Firefox 154 has enough security fixes to make restarting worth it
Mozilla released Firefox 154 with a long high-impact security advisory covering a sandbox escape, privilege-escalation bugs, use-after-free flaws, site-isolation problems, information disclosure and other issues. Mozilla has not said these vulnerabilities are being actively exploited, which is worth saying before a pile of CVE numbers turns into an imaginary apartment fire.
Still, browsers deserve more urgency than most software because their entire job is parsing complicated, untrusted material from the internet all day. Firefox ESR users also have patched releases available.
For ordinary users, the advice is gloriously boring: update Firefox and restart it. Yes, even if that means finally finding out whether all 47 tabs come back.
Friday’s stories cover medicine, AI, app-store policy and browser security, but there is a decent common thread underneath them: the interesting part of technology is usually not the headline claim. It is the qualification immediately after it. A promising cancer result still needs full data. A fixed AI bug still exposes a design risk. More App Store competition still comes with fees. A scary browser advisory still needs context. That little bit of friction between “wow” and “what does this actually mean?” is where most of the useful information lives.
Still in a reading mood? The Raymond Tec News archive covers security, AI, small-business technology, policy, and the places technology collides with ordinary life — without requiring a computer-science degree to get through it.
Sources / Further Reading
Personalized mRNA melanoma therapy
- Moderna: Phase 3 intismeran autogene results
- Reuters: Merck, Moderna say melanoma treatment meets goals in large trial
Copilot Personal / CoSnitch
Apple’s EU App Store terms
- Apple Developer: New EU business terms
- Apple Developer: Apps in the EU
- Reuters: Apple changes fees for alternative app stores in EU
